Other pharmacological treatments for motor complications and dyskinesias

Movement Disorders

Volumn 20, Issue SUPPL. 11, 2005, Pages

  Waters, Cheryl ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Dyskinesias; Motor complications; Parkinson's disease; Wearing off

Indexed keywords

AMANTADINE; APOMORPHINE; BOTULINUM TOXIN; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CLOZAPINE; DEXTROMETHORPHAN; DEXTRORPHAN; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; ISTRADEFYLLINE; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; N 9023; PLACEBO; PROPRANOLOL; RASAGILINE; RILUZOLE; ROTIGOTINE; SELEGILINE;

ADJUVANT THERAPY; ANKLE EDEMA; ARTICLE; AUTONOMIC DYSFUNCTION; CHOREA; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DIETARY INTAKE; DISEASE COURSE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG METABOLISM; DRUG TRANSPORT; DYSKINESIA; DYSPNEA; DYSTONIA; EOSINOPHILIA; FOOD DRUG INTERACTION; HALLUCINATION; HUMAN; HYPERSALIVATION; INSOMNIA; LIVEDO RETICULARIS; MENTAL DISEASE; MOTOR DYSFUNCTION; NIGHTMARE; NONHUMAN; ORTHOSTATIC HYPOTENSION; PAIN; PARESTHESIA; PARKINSON DISEASE; PRIORITY JOURNAL; SEDATION; SENSORY DYSFUNCTION; SIDE EFFECT; SKIN MANIFESTATION; SOMNOLENCE; SWEATING; TACHYCARDIA; TASTE DISORDER;

AMANTADINE; ANTIPARKINSON AGENTS; CATECHOL O-METHYLTRANSFERASE; DOPAMINE AGONISTS; DYSKINESIA, DRUG-INDUCED; GAIT; HUMANS; LEVODOPA; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE; PERIODICITY; PURINES; RECEPTORS, PURINERGIC P1; SELEGILINE;

EID: 20544477648     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20462     Document Type: Article

References (73)

1. Chase TN, Mouradian MM, Engber TM. Motor response complications and the function of striatal efferent systems. Neurology 1993;43(Suppl. 6):S23-S26.
2. Lang AE, Lozano AM. Medical progress: Parkinson's disease-I. N Engl J Med 1998;339:1044-1058.
3. Lang AE, Lozano AM. Medical progress: Parkinson's disease-II. N Engl J Med 1998;339:1130-1143.
4. Stacy M, Brownlee HJ. Treatment options for early Parkinson's disease. Am Fam Physician 1996;53:1281-1287.
5. Contin M, Riva R, Martinelli P, Albani F, Baruzzi A. Effect of meal timing on the kinetic-dynamic profile of levodopa-carbidopa controlled release in parkinsonian patients. Eur J Clin Pharmacol 1998;54:303-308.
6. Muenter MD, Sharpless NS, Tyce GM. Plasma 3-0-methyldopa in L-dopa therapy of Parkinson's disease. Mayo Clin Proc 1972;47: 389-395.
7. Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson JL. The "on-off" phenomenon in Parkinson's disease. N Engl J Med 1984;310:483-488.
8. Luquin MR, Scipioni O, Vanmonde J, Gershanik O, Obeso JA. Levodopa induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Mov Disord 1992;7:117-124.
9. Stern MB. Sinemet CR: rationale and clinical experience. Neurology 1993;43(Suppl. 1):S34-S35.
10. Riley DE, Lang AE. The spectrum of levodopa-related fluctuations in Parkinson's disease. Neurology 1993;43:1459-1464.
11. Waters CH. Managing the late complications of Parkinson's disease. Neurology 1997;49(Suppl. 1):S49-S57.
12. Koller WC, Pahwa R. Treating motor fluctuations with controlled release levodopa preparations. Neurology 1994;44(Suppl. 6): S323-S328.
13. Pahwa R, Lyons K, McGuire D, Dubinsky R, Hubble JP, Koller WC. Early morning akinesia in Parkinson's disease. Neurology 1996;46:1059-1062.
14. Shannon KM, Goetz CG, Carroll VS, Tanner CM, Klawans HL. Amantadine and motor fluctuations in chronic Parkinson's disease. Clin Neuropharmacol 1987;10:522-526.
15. Olanow W, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001;56(Suppl. 11):S1-S88.
16. Hubble JP. Novel drugs for Parkinson's disease. Med Clin North Am 1999;83:515-536.
17. Eldepryl capsule product labeling. Tampa Florida: Somerset Pharmaceuticals Inc. 1998.
18. Lees AJ, Shaw KM, Kohout LJ, et al. Deprenyl in Parkinson's disease. Lancet 1977;2:791-795.
19. Golbe LI, Lieberman AN, Meunter MD, et al. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Neurology 1988;11:45-55.
20. Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. J Pharm Pharmacol 1998;50:375-382.
21. Waters CH, Kapil D, Hauser RA, Molho E, Bertoni JM, and the Zydis selegiline study group. Zydis selegiline reduces "off" time in Parkinson's disease patients with motor fluctuations: a 3 month, randomized placebo controlled study. Mov Disord 2004;19:426-432.
22. Speiser Z, Levy R, Cohen S. Effects of N-propargyl-1R(+) aminoindan (rasagiline) in models of motor and cognition disorders. J Neural Transm Suppl 1998;52:287-300.
23. Maruyama W, Yamamoto T, Kitam K, Carrillo C, Yuodim M, Naoi AM. Mechanism underlying anti-apoptotic activity of a (-) deprenyl-related propargylamine, rasagiline. Mech Ageing Dev 2000;116:181-191.
24. Abu-Raya S, Tabakman R, Balgrund E, Trembovler V, Lazarovici P. Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells. Eur J Pharmacol 2002;434:109-116.
25. Abu-Raya S, Balugrund E, Trembovler V, Lazarovici P. Rasagiline, a novel monoamine oxidase-B inhibitor with neuroprotective effects under ischemic conditions in PC12 cells. Drug Dev Res 2000;50:285-290.
26. Rabey JM, Sagi I, Huberman M, et al, on behalf of the rasagiline study group. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjuncfive therapy to levodopa. Clin Neuropharmacol 2000;23:324-330.
27. Parkinson Study Group. A randomized placebo controlled trial of rasagiline in Parkinson's disease patients with levodopa related motor fluctuations. The PRESTO study. Arch Neurol 2005;62: 241-248.
28. Rascol O, Brooks DJ, Melamed E, et al. A comparative randomized study of rasagiline versus placebo or entacapone as adjunct to levodopa in Parkinson's disease (PD) patients with motor fluctuations. European Federation of Neurological Sciences, Sept 2, 2003.
29. Hutton IT, Metman LV, Thomas NC, et al. Transdermal dopaminergic D2 receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled study. Mov Disord 2001;16:459-463.
30. Metman LV, Gillespie M, Farmer C, et al. Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease. Clin Neuropharmacol 2001;24:163-169.
31. Hauser RA, Hubble JP, Truong DD. Istradefylline US-001 Study Group. Randomized trial of the adenosine A (2A) receptor antagonist istradefylline in advanced PD. Neurology 2003;61:297-303.
32. Metman LV, Hoff J, Mouradian MM, Chase TN. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa-carbidopa. Mov Disord 1994;9:463-465.
33. Kurth MC, Tetrud JW, Irwin I, Lyness WH, Langston JW. Oral levodopa-carbidopa solution versus tablets in Parkinson's patients with severe fluctuations - a pilot study. Neurology 1993;43:1036-1039.
34. Pappert EJ, Buhrfiend C, Lipton JW, Carvey PM, Stebbins GT, Goetz CG. Levodopa stability in solution: time course, environmental effect, and practical recommendations for clinical use. Mov Disord 1996;11:24-26.
35. Sage JI, McHale DM, Sonsalla P, Vitagliano D, Heikkila RE. Continuous levodopa infusions to treat complex dystonia in Parkinson's disease. Neurology 1989;39:888-891.
36. Sage JI, Trooskin S, Sonsalla PK, Heikkila RE. Experience with continuous enteral levodopa infusions in die treatment of 9 patients with advanced Parkinson's disease. Neurology 1989;39(Suppl. 2): 60-63.
37. Bredberg E, Nilsson D, Johansson K, Aquilonius SM, Johnels B, Nystrom C, Paalzow L. Intraduodenal infusion of a water-based levodopa dispersion for optimization of the therapeutic effect in severe Parkinson's disease. Eur J Clin Pharmacol 1993;45:117-122.
38. Kurth MC, Tetrud JW, Tanner CM, et al. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa-carbidopa in Parkinson's disease patients with on-off fluctuations. Neurology 1993;43:1698-1703.
39. Colosimo C, Merello M, Albanese A. Clinical usefulness of apomorphine in movement disorders. Clin Neuropharmacol 1994;17: 243-259.
40. Frankel JP, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 1990;53:96-101.
41. Metman LV, Locatelli ER, Bravi D, Mouradian MM, Chase TN. Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications. Neurology 1997;48:369-372.
42. Sherry JH, Durham NC, Guyton PJ, Morgantown WV, Van Lunen B, Bottini PB. Continued efficacy and safety of subcutaneous injections of apomorphine in the treatment of off episodes in patients with Parkinson's disease. Neurology 2003;60(Suppl. 1): S09.005.
43. Chaudburi KR, Clough C. Subcutaneous apomorphine in Parkinson's disease. BMJ 1998;316:641.
44. Brennan J, editor. Modern prescribing: apomorphine (Britaject). In: Parkinson's disease. Kent: Medpress Ltd; 1996. p 4.
45. Ondo W, Hunter C, Almaguer M, Jankovic J. A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's disease. Mov Disord 1999;14:664-668.
46. Priano L, Albani G, Calderoni S, et al. Controlled-release transdermal apomorphine treatment for motor fluctuations in Parkinson's disease. Neurol Sci 2002;23(Suppl. 2):S99-S100.
47. Fahn S. The freezing phenomenon in parkinsonism. Adv Neurol 1995;67:53-63.
48. Narabayashi H, Kondo T, Yokochi F, Nagatsu T. Clinical effects of L-threo-3,4-dihydroxyphenylserine in cases of parkinsonism and pure akinesia. Adv Neurol 1986;45:593-602.
49. Giladi N, Gurevich T, Shabtai H, Paleacu D, Simon ES. The effect of botulinum toxin injections to the calf muscles on freezing of gait in parkinsonism: a pilot study. J Neurol 2001;248:572-576.
50. Horstink MWIM, Zijlmans JCM, Pasman JW, Berger HJC. Vanthof MA. Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia. J Neurol Neurosurg Psychiatry 1990;53: 224-226.
51. Blanchet PJ, Allard P, Gregoire L, Tardif F, Bedard PJ. Risk factors for peak dose dyskinesia in 100 levodopa-treated patients. Can J Neurol Sci 1996;23:189-193.
52. Nutt JG, Woodward WR, Anderson IL. The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism. Ann Neurol 1985;18:527-543.
53. Rajput A, Wallukait M, Rajput AH. 18 month prospective study of amantadine (Amd) for dopa (LD) induced dyskinesias (DK) in idiopathic Parkinson's disease. Can J Neurol Sci 1997;24:S23.
54. Metman LV, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998;50: 1323-1326.
55. Metman LV, Del Dotto P, LePoole K, Konitsiotis S, Fang J, Chase TN. Amantadine for levodopa induced dyskinesias: a 1-year follow-up study. Arch Neurol 1999;56:1383-1386.
56. Snow BJ, Macdonald L, Mcauley D, Wallis W. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. Clin Neuropharmacol 2000;23:82-85.
57. Luginger E, Weaning GK, Bosch S, Poewe W. Beneficial effects of amantadine on L-Dopa-induced dyskinesias in Parkinson's disease. Mov Disord 2000;15:873-878.
58. Metman LV, Konitsiotis S, Chase TN. Pathophysiology of motor response complications in Parkinson's disease: hypotheses on the why, where, and what. Mov Disord 2000;15:3-8.
59. Thomas A, Iacono D, Luciano AL. Armellino K, Di Iorio A, Onofrj M. Duration of amantadine benefit on dyskinesia of severe Parkinson disease. J Neurol Neurosurg Psychiatry 2004;75:141-143.
60. Crosby NJ, Deane KH, Clarke CE. Amantadine for dyskinesia in Parkinson's disease Cochrane Database Syst Rev 2003;(2): CD003467.
61. Goetz CG, Koller WC, Poewe W, Rascol O, Sampaio C. Amantadine and other Antiglutamate agents. Mov Disord 2002; 17(Suppl. 4):S13-522.
62. Metman LV, Del Dotto P, Natte R, van den Munckhof P, Chase TN. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease. Neurology 1998;51:203-206.
63. Metman LV, Del Dotto P, Blanchet PJ, van den Munckhof P, Chase TN. Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Amino Acids 1998;14:75-82.
64. Merims D, Ziv I, Djaldetti R, Melamed E. Riluzole for levodopa-induced dyskinesias in advanced Parkinson's disease. Lancet 1999; 353:1764-1765.
65. Bennett JP, Landow ER, Schuh LA. Suppression of dyskinesias in advanced Parkinson's disease. II. Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms. Neurology 1993;43:1551-1555.
66. Bennett JP, Landow ER, Dietrich S, Schuh LA. Suppression of dyskinesias in advanced Parkinson's disease: moderate daily clozapine doses provide long-term dyskinesia reduction. Mov Disord 1994;9:409-414.
67. Durif F, Vidailhet M, Assal F, Roche C, Bonnet AM, Agid Y. Low-dose clozapine improves dyskinesias in Parkinson's disease. Neurology 1997;48:658-662.
68. Pierelli F, Adipietro A, Soldati G, Fattapposta F, Pozzessere G, Scoppetta C. Low dosage clozapine effects on L-dopa induced dyskinesias in parkinsonian patients. Acta Neurol Scand 1998;97: 295-299.
69. Durif F, Debilly B, Galitzky M, et al. Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology 2004;62:381-388.
70. Carpentier AF, Bonnet AM, Vidailhet M, Agid Y. Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease. Neurology 1996:46:1548-1551.
71. Muenter MD, Sharpless NS, Tyce GM, Darley FL. Patterns of dystonia ("I-D-1" and "D-1-D") in response to L-dopa therapy of Parkinson's disease. Mayo Clin Proc 1977;52:163-174.
72. Lhermitte F, Agid Y, Signoret JL. Onset and end-of-dose levodopa-induced dyskinesias. Arch Neurol 1978;35:261-262.
73. Marsden CD, Parkes JD, Quinn N. Fluctuations of disability in Parkinson's disease: clinical aspects. In: Marsden CD, Fahn S, editors. Movement disorders. London: Butterworth Scientific; 1982. p 96-122.